The extensive expression of PDE4 in the basal ganglia and its role in modulating adenosine and DA signaling pathways support further research for developing more selective and better-tolerated PDE4 inhibitors as potential therapeutic agents for PD. Here, PDE4A is linked to Parkinson disease.